NASDAQ:MYL - Mylan Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $38.41 +0.26 (+0.68 %) (As of 08/20/2018 04:00 PM ET)Previous Close$38.15Today's Range$38.16 - $38.8052-Week Range$29.53 - $47.82Volume2.77 million shsAverage Volume4.90 million shsMarket Capitalization$19.18 billionP/E Ratio8.40Dividend YieldN/ABeta1.34 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. Receive MYL News and Ratings via Email Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:MYL CUSIP62853010 Webwww.mylan.com Phone44-0-17-0785-3000 Debt Debt-to-Equity Ratio1.18 Current Ratio1.29 Quick Ratio0.77 Price-To-Earnings Trailing P/E Ratio8.40 Forward P/E Ratio8.07 P/E Growth1.16 Sales & Book Value Annual Sales$11.91 billion Price / Sales1.66 Cash Flow$8.1723 per share Price / Cash4.70 Book Value$24.81 per share Price / Book1.55 Profitability EPS (Most Recent Fiscal Year)$4.56 Net Income$696 million Net Margins3.90% Return on Equity18.48% Return on Assets6.86% Miscellaneous Employees35,000 Outstanding Shares515,570,000Market Cap$19.18 billion Mylan (NASDAQ:MYL) Frequently Asked Questions What is Mylan's stock symbol? Mylan trades on the NASDAQ under the ticker symbol "MYL." How were Mylan's earnings last quarter? Mylan NV (NASDAQ:MYL) released its earnings results on Wednesday, August, 8th. The company reported $1.07 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.22 by $0.15. The business had revenue of $2.81 billion for the quarter, compared to analysts' expectations of $2.95 billion. Mylan had a return on equity of 18.48% and a net margin of 3.90%. The business's quarterly revenue was down 5.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.10 earnings per share. View Mylan's Earnings History. When is Mylan's next earnings date? Mylan is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Mylan. What guidance has Mylan issued on next quarter's earnings? Mylan updated its FY18 earnings guidance on Wednesday, August, 8th. The company provided EPS guidance of $4.55-4.90 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.25. The company issued revenue guidance of $11.25-12.25 billion, compared to the consensus revenue estimate of $12.19 billion. What price target have analysts set for MYL? 20 analysts have issued 1 year target prices for Mylan's stock. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's stock price to reach $46.6521 in the next year. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Mylan. What is the consensus analysts' recommendation for Mylan? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mylan. What are Wall Street analysts saying about Mylan stock? Here are some recent quotes from research analysts about Mylan stock: 1. Cantor Fitzgerald analysts commented, ". We are reiterating our Neutral rating and $41 12-month price target following MYL’s 2Q18 EPS miss and management’s lowering of its 2018 financial guidance. MYL has a robust business model. That said, the risk/reward is already reflected in the company’s valuation, in our view. We could still become more constructive on the stock if new product opportunities exceed expectations and/ or U.S. generic drug pricing improves." (8/8/2018) 2. Guggenheim analysts commented, "We spoke with two oncologists in different practice settings regarding their potential use of Fulphila. While biosimilar financial incentives will play a role in Fulphila’s adoption, the Onpro device appears entrenched in current clinical practice. For that and other reasons, we believe that it might be more prudent to take a conservative approach to Fulphila’s uptake at the outset. We maintain our BUY rating on shares of Mylan. Consultant Commentary: We spoke with two oncologists on their respective academic and rural private practice settings. The academic consultant saw roughly 100 Neulasta patients per month while the rural oncologist saw ~30 Neulasta patients per month." (6/14/2018) 3. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018) 4. Argus analysts commented, "junior version" (8/22/2017) Are investors shorting Mylan? Mylan saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 9,703,368 shares, a drop of 16.3% from the July 13th total of 11,598,086 shares. Based on an average daily trading volume, of 3,251,151 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.0% of the shares of the stock are short sold. View Mylan's Current Options Chain. Who are some of Mylan's key competitors? Some companies that are related to Mylan include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS) and Merck KGaA (MKGAF). Who are Mylan's key executives? Mylan's management team includes the folowing people: Ms. Heather Bresch, CEO & Exec. Director (Age 49)Mr. Rajiv Malik, Pres & Exec. Director (Age 57)Mr. Kenneth S. Parks, Chief Financial Officer (Age 55)Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 45)Mr. Anthony Mauro, Chief Commercial Officer (Age 45) Has Mylan been receiving favorable news coverage? News articles about MYL stock have trended somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan earned a coverage optimism score of 0.20 on Accern's scale. They also assigned media stories about the company an impact score of 46.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Mylan. Who are Mylan's major shareholders? Mylan's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.73%), Pzena Investment Management LLC (4.10%), Bank of New York Mellon Corp (1.83%), FMR LLC (1.78%), Menora Mivtachim Holdings LTD. (1.36%) and Janus Henderson Group PLC (1.05%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan. Which major investors are selling Mylan stock? MYL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Wells Fargo & Company MN, Laurion Capital Management LP, Bank of Montreal Can, Point72 Asset Management L.P., Ivory Investment Management LLC, Los Angeles Capital Management & Equity Research Inc. and Bank of Nova Scotia. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan. Which major investors are buying Mylan stock? MYL stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Orbimed Advisors LLC, Kornitzer Capital Management Inc. KS, Clal Insurance Enterprises Holdings Ltd, Dimensional Fund Advisors LP, Advisors Asset Management Inc., Great West Life Assurance Co. Can and Bellevue Group AG. View Insider Buying and Selling for Mylan. How do I buy shares of Mylan? Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mylan's stock price today? One share of MYL stock can currently be purchased for approximately $38.41. How big of a company is Mylan? Mylan has a market capitalization of $19.18 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe. How can I contact Mylan? Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected] MarketBeat Community Rating for Mylan (NASDAQ MYL)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 621 (Vote Outperform)Underperform Votes: 476 (Vote Underperform)Total Votes: 1,097MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: Should I invest in "strong buy" stocks?